Arrowhead Gains Full Rights to ARO-PNPLA3 for Patients with Non-Alcoholic Steatohepatitis
Shots:
- ARO-PNPLA3, formerly known as JNJ-75220795 which was part of a 2018 research collaboration and option agreement b/w Arrowhead and Janssen has been acquired by Arrowhead.
- ARO-PNPLA3 showed encouraging results after a single dose in a P-I study incl. 40% mean reduction in liver fat in PNPLA3 I148M homozygotes, no clinical changes or trends in any safety parameters with no tolerability issues, no AEs leading to treatment or study discontinuation & no apparent treatment-emergent increases in triglycerides or LDL-cholesterol
- ARO-PNPLA3, an RNAi therapeutic that was developed using Arrowhead’s TRiM platform. The therapy has the potential to reduce liver expression of PNPLA3 for NASH
Ref: Businesswire | Image: Arrowhead
Related News:- Arrowhead and Takeda Report P-II Study (SEQUOIA) of Fazirsiran for Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
